glp-1 drugs mounjaro FDA approves new version of diabetes drug to be sold for weight loss WHO backs weight-loss drugs to

In March 2024, Viking Therapeutics announced positive results from the company's Phase I multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 , a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic disorders such as obesity

Results Generation of potent GLP-1R and GIPR dual agonists Our primary objective was to design a GLP-1R and GIPR dual agonist while minimizing its effect on GCGR

Prioritize protein, vegetables, and whole foods

Rising costs lead insurers to drop weight loss drug coverage, further increasing patient burden

Neuroprotective Effects of GLP-1 Receptor Agonists in Neurodegenerative Disorders: A Large-Scale Propensity-Matched Cohort Study

Berberine : Berberine is a compound found in plants like goldenseal and barberry